<DOC>
	<DOCNO>NCT02576509</DOCNO>
	<brief_summary>The purpose study determine nivolumab sorafenib effective treatment Advanced Hepatocellular Carcinoma . NOTE : Global recruitment complete enrollment ongoing China sub-study .</brief_summary>
	<brief_title>An Investigational Immuno-therapy Study Nivolumab Compared Sorafenib First Treatment Patients With Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com NOTE : Global recruitment complete enrollment ongoing China substudy Histologically confirm advanced hepatocellular carcinoma , eligible surgical and/or locoregional therapy ; progressive disease surgical /or locoregional therapy Locoregional therapy hepatocellular carcinoma ( HCC ) must complete least 4 week prior baseline scan ChildPugh Class A Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 1 Known fibrolamellar HCC , sarcomatoid HCC , mixed cholangiocarcinoma HCC Prior liver transplant Active , know , suspect autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>